Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Columbia University |
---|---|
Information provided by: | Columbia University |
ClinicalTrials.gov Identifier: | NCT00408447 |
Sickle cell disease is a genetic disorder in which a mutation in the beta chain of human hemoglobin results in abnormal blood hemoglobin, causing red blood cells to sickle under stress with resulting symptoms including severe pains and strokes. Beta thalassemia is another genetic disorder in which there are abnormal beta hemoglobin chains, causing anemia. In both disorders, frequent red blood cell transfusions may be required to sustain life, but these often result in complications including multiple hospitalizations, iron overload, or bacterial or viral infections such as hepatitis. Standard drugs and therapies used in the treatment of sickle cell disease and/or beta thalassemia provide only supportive care, and may result in long-term side effects, and inadequate control of the disease process. Bone marrow transplant has been increasingly used for the long-term treatment and cure of sickle cell disease and beta thalassemia. Although, not without acute and potential long term side effects, this alternative offers long term control and potential cure of the disease. Most of the side effects seen with bone marrow transplant are directly related to the high intensity of chemotherapy used (ablative).
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease. Patients will receive a chemotherapy regimen with busulfan, fludarabine, and alemtuzumab followed by an infusion of stem cells, either from a family-related or cord-blood matched donor.
Condition | Intervention | Phase |
---|---|---|
Sickle Cell Disease Beta Thalassemia |
Drug: Busulfan Drug: Fludarabine Drug: Alemtuzumab Procedure: Allogeneic stem cell transplant |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia |
Estimated Enrollment: | 60 |
Study Start Date: | December 2001 |
Estimated Study Completion Date: | January 2012 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
Sickle Cell Disease
|
Drug: Busulfan
Busulfan 4 mg/kg/d x 4d
Drug: Fludarabine
Fludarabine 30 mg/m2/d x 6d
Drug: Alemtuzumab
Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
Procedure: Allogeneic stem cell transplant
Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative), sibling cord blood donor or cryopreserved unrelated cord blood unit.
|
2
Beta Thalassemia
|
Drug: Busulfan
Busulfan 4 mg/kg/d x 4d
Drug: Fludarabine
Fludarabine 30 mg/m2/d x 6d
Drug: Alemtuzumab
Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
Procedure: Allogeneic stem cell transplant
Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative), sibling cord blood donor or cryopreserved unrelated cord blood unit.
|
Further study details will be provided by Columbia University, Division of Pediatric Blood & Marrow Transplantation.
STUDY DESIGN:
Patients will receive busulfan, fludarabine and alemtuzumab prior to the stem cell transplant to help the stem cells take and grow. The stem cells will be infused on day 0 through an intravenous catheter. Patients will receive immunosuppressive therapy such as tacrolimus and MMF to prevent graft-versus-disease.
Patients will be followed up after transplant to look for special cells in the blood that show that the new bone marrow is taking hold (engrafting). Response shall be documented at 6 months, 1 year, 2 years and 3 years post-SCT.
Ages Eligible for Study: | 1 Month to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Sickle Cell Disease:
MINIMUM OF ONE OF THE FOLLOWING CRITERIA:
Sickle Nephropathy:
Thalassemia Homozygous B-thalassemia Clinical syndrome of B-thalassemia intermedia (including double heterozygotes, e.g. Hgb E-Beta thalassemia) who either:
and
Patient must have adequate organ function as below:
Adequate renal function defined as:
Adequate liver function defined as:
Adequate cardiac function defined as:
Adequate pulmonary function defined as:
Exclusion Criteria:
General
Sickle Cell Disease
Thalassemia
Contact: Monica Bhatia, MD | 212 305 9138 | mb2476@columbia.edu |
Contact: William A Kim, Ph.D. | 212-305-7213 | billkim@columbia.edu |
United States, New York | |
Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University | Recruiting |
New York, New York, United States, 10032 | |
Contact: Monica Bhatia, MD 212-305-9138 mb2476@columbia.edu | |
Contact: William A Kim, Ph.D. 212-305-7213 billkim@columbia.edu | |
Principal Investigator: Monica Bhatia, MD | |
Sub-Investigator: Mitchell S. Cairo, MD |
Study Chair: | Mitchell S. Cairo, MD | Columbia University |
Responsible Party: | Columbia University ( Monica Bhatia, MD ) |
Study ID Numbers: | CHNY-01-503, IRB#AAAA7701 |
Study First Received: | December 6, 2006 |
Last Updated: | August 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00408447 History of Changes |
Health Authority: | United States: Institutional Review Board |
stem cell transplant sickle cell disease thalassemia |
moderately ablative cord blood transplant matched family donor |
Antimetabolites Immunologic Factors Hematologic Diseases Beta-thalassemia Anemia Anemia, Hemolytic Fludarabine monophosphate Immunosuppressive Agents Thalassemia Anemia, Hemolytic, Congenital Thalassemia Minor |
Genetic Diseases, Inborn Busulfan Alemtuzumab Beta-Thalassemia Hemoglobinopathies Sickle Cell Anemia Antineoplastic Agents, Alkylating Fludarabine Hemoglobinopathy Alkylating Agents Anemia, Sickle Cell |
Antimetabolites Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Alemtuzumab Therapeutic Uses Anemia, Sickle Cell Alkylating Agents Hematologic Diseases Anemia Anemia, Hemolytic |
Fludarabine monophosphate Thalassemia Immunosuppressive Agents Pharmacologic Actions Anemia, Hemolytic, Congenital Genetic Diseases, Inborn Busulfan Hemoglobinopathies Beta-Thalassemia Myeloablative Agonists Fludarabine Antineoplastic Agents, Alkylating |